Global Liver Fibrosis Drug

Liver Fibrosis Drug Comprehensive Study by Type (Interferon, Maloti Lipid, Nucleoside, Other), Application (Hospital, Clinic, Research Center), Diagnosis (Liver Biopsy, Transient Elastography, Nonsurgical Tests) Players and Region - Global Market Outlook to 2030

Liver Fibrosis Drug Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 11%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Liver fibrosis is the scarring process that signifies the livers response to injury. As skin and other organs heal injuries through deposition of collagen same way the liver repairs injury through the deposition of new collagen. Fibrosis is the term used to describe mild scarring in the liver, which happens when the liver is repeatedly or continuously damaged. Hepatotropic drug enables safe and efficient treatment for reducing fibrosis in patients. According to AMA Research, the market for Liver Fibrosis Drug is expected to register a CAGR of 11.0% during the forecast period to 2030. This growth is primarily driven by Increasing Prevalence of Liver Diseases.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Bristol-Myers Squibb Company (United States), Gilead Sciences, Inc. Company (United States), Pharmaxis Limited (Australia), LG Life Science Ltd. (South Korea), Novartis AG (Switzerland), Vertex Pharmaceuticals Incorporated (United States), Biotest (Germany), GlaxoSmithkline (United Kingdom), Merck & Co. (United States) and Digna Biotech, S.L. (Spain), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
January 9, 2019: Gilead Sciences, Inc. and Yuhan Corporation announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
In January 2024, Boehringer Ingelheim signed a partnership deal with Suzhou Ruibo Biotechnology and its subsidiary Ribocure Pharmaceuticals to discover and develop siRNA therapeutics for liver fibrosis.The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail competitive advantage through combined collaborations.

Regulatory Insights:
FDA encourages the sponsor to use animal models for NASH to screen and identify potential investigational drugs. The sponsor should select a specific animal model based on the mechanism of action of the investigational drug.

Influencing Trend:
Increasing Risk of Lung Cancer

Market Growth Drivers:
Increasing Prevalence of Liver Diseases

Challenges:
Risks of Side-Effects Associated with Liver Disease Medications and Liver Fibrosis may cause Liver Cirrhosis

Restraints:
High Cost Incurred in Research and Development

Opportunities:
Rising R&D Investments for the Development of Novel Therapies

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Liver Fibrosis Drug Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Liver Fibrosis Drug Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Liver Fibrosis Drug players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Liver Fibrosis Drug Study Sheds Light on
— The Liver Fibrosis Drug Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Liver Fibrosis Drug industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Liver Fibrosis Drug industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Interferon
  • Maloti Lipid
  • Nucleoside
  • Other
By Application
  • Hospital
  • Clinic
  • Research Center
By Diagnosis
  • Liver Biopsy
  • Transient Elastography
  • Nonsurgical Tests

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Liver Diseases
    • 3.3. Market Challenges
      • 3.3.1. Risks of Side-Effects Associated with Liver Disease Medications
      • 3.3.2. Liver Fibrosis may cause Liver Cirrhosis
    • 3.4. Market Trends
      • 3.4.1. Increasing Risk of Lung Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Liver Fibrosis Drug, by Type, Application, Diagnosis and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Liver Fibrosis Drug (Value)
      • 5.2.1. Global Liver Fibrosis Drug by: Type (Value)
        • 5.2.1.1. Interferon
        • 5.2.1.2. Maloti Lipid
        • 5.2.1.3. Nucleoside
        • 5.2.1.4. Other
      • 5.2.2. Global Liver Fibrosis Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Research Center
      • 5.2.3. Global Liver Fibrosis Drug by: Diagnosis (Value)
        • 5.2.3.1. Liver Biopsy
        • 5.2.3.2. Transient Elastography
        • 5.2.3.3. Nonsurgical Tests
      • 5.2.4. Global Liver Fibrosis Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Liver Fibrosis Drug (Price)
      • 5.3.1. Global Liver Fibrosis Drug by: Type (Price)
  • 6. Liver Fibrosis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gilead Sciences, Inc. Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pharmaxis Limited (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. LG Life Science Ltd. (South Korea)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Vertex Pharmaceuticals Incorporated (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biotest (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithkline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Digna Biotech, S.L. (Spain)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Liver Fibrosis Drug Sale, by Type, Application, Diagnosis and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Liver Fibrosis Drug (Value)
      • 7.2.1. Global Liver Fibrosis Drug by: Type (Value)
        • 7.2.1.1. Interferon
        • 7.2.1.2. Maloti Lipid
        • 7.2.1.3. Nucleoside
        • 7.2.1.4. Other
      • 7.2.2. Global Liver Fibrosis Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Research Center
      • 7.2.3. Global Liver Fibrosis Drug by: Diagnosis (Value)
        • 7.2.3.1. Liver Biopsy
        • 7.2.3.2. Transient Elastography
        • 7.2.3.3. Nonsurgical Tests
      • 7.2.4. Global Liver Fibrosis Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Liver Fibrosis Drug (Price)
      • 7.3.1. Global Liver Fibrosis Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Liver Fibrosis Drug: by Type(USD Million)
  • Table 2. Liver Fibrosis Drug Interferon , by Region USD Million (2018-2023)
  • Table 3. Liver Fibrosis Drug Maloti Lipid , by Region USD Million (2018-2023)
  • Table 4. Liver Fibrosis Drug Nucleoside , by Region USD Million (2018-2023)
  • Table 5. Liver Fibrosis Drug Other , by Region USD Million (2018-2023)
  • Table 6. Liver Fibrosis Drug: by Application(USD Million)
  • Table 7. Liver Fibrosis Drug Hospital , by Region USD Million (2018-2023)
  • Table 8. Liver Fibrosis Drug Clinic , by Region USD Million (2018-2023)
  • Table 9. Liver Fibrosis Drug Research Center , by Region USD Million (2018-2023)
  • Table 10. Liver Fibrosis Drug: by Diagnosis(USD Million)
  • Table 11. Liver Fibrosis Drug Liver Biopsy , by Region USD Million (2018-2023)
  • Table 12. Liver Fibrosis Drug Transient Elastography , by Region USD Million (2018-2023)
  • Table 13. Liver Fibrosis Drug Nonsurgical Tests , by Region USD Million (2018-2023)
  • Table 14. South America Liver Fibrosis Drug, by Country USD Million (2018-2023)
  • Table 15. South America Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 16. South America Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 17. South America Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 18. Brazil Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 19. Brazil Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 20. Brazil Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 21. Argentina Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 22. Argentina Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 23. Argentina Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 24. Rest of South America Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 27. Asia Pacific Liver Fibrosis Drug, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 31. China Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 32. China Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 33. China Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 34. Japan Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 35. Japan Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 36. Japan Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 37. India Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 38. India Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 39. India Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 40. South Korea Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 41. South Korea Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 42. South Korea Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 43. Taiwan Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 44. Taiwan Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 45. Taiwan Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 46. Australia Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 47. Australia Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 48. Australia Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 52. Europe Liver Fibrosis Drug, by Country USD Million (2018-2023)
  • Table 53. Europe Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 54. Europe Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 55. Europe Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 56. Germany Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 57. Germany Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 58. Germany Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 59. France Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 60. France Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 61. France Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 62. Italy Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 63. Italy Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 64. Italy Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 65. United Kingdom Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 68. Netherlands Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 69. Netherlands Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 70. Netherlands Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 71. Rest of Europe Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 74. MEA Liver Fibrosis Drug, by Country USD Million (2018-2023)
  • Table 75. MEA Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 76. MEA Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 77. MEA Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 78. Middle East Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 79. Middle East Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 80. Middle East Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 81. Africa Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 82. Africa Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 83. Africa Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 84. North America Liver Fibrosis Drug, by Country USD Million (2018-2023)
  • Table 85. North America Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 86. North America Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 87. North America Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 88. United States Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 89. United States Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 90. United States Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 91. Canada Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 92. Canada Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 93. Canada Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 94. Mexico Liver Fibrosis Drug, by Type USD Million (2018-2023)
  • Table 95. Mexico Liver Fibrosis Drug, by Application USD Million (2018-2023)
  • Table 96. Mexico Liver Fibrosis Drug, by Diagnosis USD Million (2018-2023)
  • Table 97. Liver Fibrosis Drug: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Liver Fibrosis Drug: by Type(USD Million)
  • Table 109. Liver Fibrosis Drug Interferon , by Region USD Million (2025-2030)
  • Table 110. Liver Fibrosis Drug Maloti Lipid , by Region USD Million (2025-2030)
  • Table 111. Liver Fibrosis Drug Nucleoside , by Region USD Million (2025-2030)
  • Table 112. Liver Fibrosis Drug Other , by Region USD Million (2025-2030)
  • Table 113. Liver Fibrosis Drug: by Application(USD Million)
  • Table 114. Liver Fibrosis Drug Hospital , by Region USD Million (2025-2030)
  • Table 115. Liver Fibrosis Drug Clinic , by Region USD Million (2025-2030)
  • Table 116. Liver Fibrosis Drug Research Center , by Region USD Million (2025-2030)
  • Table 117. Liver Fibrosis Drug: by Diagnosis(USD Million)
  • Table 118. Liver Fibrosis Drug Liver Biopsy , by Region USD Million (2025-2030)
  • Table 119. Liver Fibrosis Drug Transient Elastography , by Region USD Million (2025-2030)
  • Table 120. Liver Fibrosis Drug Nonsurgical Tests , by Region USD Million (2025-2030)
  • Table 121. South America Liver Fibrosis Drug, by Country USD Million (2025-2030)
  • Table 122. South America Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 123. South America Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 124. South America Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 125. Brazil Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 126. Brazil Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 127. Brazil Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 128. Argentina Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 129. Argentina Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 130. Argentina Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 131. Rest of South America Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 132. Rest of South America Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 133. Rest of South America Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 134. Asia Pacific Liver Fibrosis Drug, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 136. Asia Pacific Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 137. Asia Pacific Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 138. China Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 139. China Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 140. China Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 141. Japan Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 142. Japan Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 143. Japan Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 144. India Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 145. India Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 146. India Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 147. South Korea Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 148. South Korea Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 149. South Korea Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 150. Taiwan Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 151. Taiwan Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 152. Taiwan Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 153. Australia Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 154. Australia Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 155. Australia Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 159. Europe Liver Fibrosis Drug, by Country USD Million (2025-2030)
  • Table 160. Europe Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 161. Europe Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 162. Europe Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 163. Germany Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 164. Germany Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 165. Germany Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 166. France Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 167. France Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 168. France Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 169. Italy Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 170. Italy Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 171. Italy Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 172. United Kingdom Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 173. United Kingdom Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 174. United Kingdom Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 175. Netherlands Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 176. Netherlands Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 177. Netherlands Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 178. Rest of Europe Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 179. Rest of Europe Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 180. Rest of Europe Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 181. MEA Liver Fibrosis Drug, by Country USD Million (2025-2030)
  • Table 182. MEA Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 183. MEA Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 184. MEA Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 185. Middle East Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 186. Middle East Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 187. Middle East Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 188. Africa Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 189. Africa Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 190. Africa Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 191. North America Liver Fibrosis Drug, by Country USD Million (2025-2030)
  • Table 192. North America Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 193. North America Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 194. North America Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 195. United States Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 196. United States Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 197. United States Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 198. Canada Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 199. Canada Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 200. Canada Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 201. Mexico Liver Fibrosis Drug, by Type USD Million (2025-2030)
  • Table 202. Mexico Liver Fibrosis Drug, by Application USD Million (2025-2030)
  • Table 203. Mexico Liver Fibrosis Drug, by Diagnosis USD Million (2025-2030)
  • Table 204. Liver Fibrosis Drug: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Liver Fibrosis Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Liver Fibrosis Drug: by Application USD Million (2018-2023)
  • Figure 6. Global Liver Fibrosis Drug: by Diagnosis USD Million (2018-2023)
  • Figure 7. South America Liver Fibrosis Drug Share (%), by Country
  • Figure 8. Asia Pacific Liver Fibrosis Drug Share (%), by Country
  • Figure 9. Europe Liver Fibrosis Drug Share (%), by Country
  • Figure 10. MEA Liver Fibrosis Drug Share (%), by Country
  • Figure 11. North America Liver Fibrosis Drug Share (%), by Country
  • Figure 12. Global Liver Fibrosis Drug: by Type USD/Units (2018-2023)
  • Figure 13. Global Liver Fibrosis Drug share by Players 2023 (%)
  • Figure 14. Global Liver Fibrosis Drug share by Players (Top 3) 2023(%)
  • Figure 15. Global Liver Fibrosis Drug share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 19. Gilead Sciences, Inc. Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Gilead Sciences, Inc. Company (United States) Revenue: by Geography 2023
  • Figure 21. Pharmaxis Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 22. Pharmaxis Limited (Australia) Revenue: by Geography 2023
  • Figure 23. LG Life Science Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 24. LG Life Science Ltd. (South Korea) Revenue: by Geography 2023
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. Vertex Pharmaceuticals Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 28. Vertex Pharmaceuticals Incorporated (United States) Revenue: by Geography 2023
  • Figure 29. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Biotest (Germany) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithkline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithkline (United Kingdom) Revenue: by Geography 2023
  • Figure 33. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 35. Digna Biotech, S.L. (Spain) Revenue, Net Income and Gross profit
  • Figure 36. Digna Biotech, S.L. (Spain) Revenue: by Geography 2023
  • Figure 37. Global Liver Fibrosis Drug: by Type USD Million (2025-2030)
  • Figure 38. Global Liver Fibrosis Drug: by Application USD Million (2025-2030)
  • Figure 39. Global Liver Fibrosis Drug: by Diagnosis USD Million (2025-2030)
  • Figure 40. South America Liver Fibrosis Drug Share (%), by Country
  • Figure 41. Asia Pacific Liver Fibrosis Drug Share (%), by Country
  • Figure 42. Europe Liver Fibrosis Drug Share (%), by Country
  • Figure 43. MEA Liver Fibrosis Drug Share (%), by Country
  • Figure 44. North America Liver Fibrosis Drug Share (%), by Country
  • Figure 45. Global Liver Fibrosis Drug: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb Company (United States)
  • Gilead Sciences, Inc. Company (United States)
  • Pharmaxis Limited (Australia)
  • LG Life Science Ltd. (South Korea)
  • Novartis AG (Switzerland)
  • Vertex Pharmaceuticals Incorporated (United States)
  • Biotest (Germany)
  • GlaxoSmithkline (United Kingdom)
  • Merck & Co. (United States)
  • Digna Biotech, S.L. (Spain)
Additional players considered in the study are as follows:
Genfit SA (France) , GNI Group Ltd. (Japan) , FibroGen, Inc. (United States) , Dr. Falk Pharma GmbH (Germany)
Select User Access Type

Key Highlights of Report


Apr 2024 236 Pages 95 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Liver Fibrosis Drug Quantitative research analysis
Global Liver Fibrosis Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2023; Base year: 2023; Forecast period: 2024 to 2030
Companies that are profiled in Global Liver Fibrosis Drug Market are Bristol-Myers Squibb Company (United States), Gilead Sciences, Inc. Company (United States), Pharmaxis Limited (Australia), LG Life Science Ltd. (South Korea), Novartis AG (Switzerland), Vertex Pharmaceuticals Incorporated (United States), Biotest (Germany), GlaxoSmithkline (United Kingdom), Merck & Co. (United States) and Digna Biotech, S.L. (Spain) etc.
Hospital segment in Global market to hold robust market share owing to "Increasing Prevalence of Liver Diseases".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Liver Fibrosis Drug market throughout the forecasted period.

Know More About Global Liver Fibrosis Drug Report?

Have a Query? Click Here

Other Related Reports

Salivary Gland Cancer Comprehensive Study by Type (Parotid glands, Submandibular glands, Sublingual glands), Application (Hospitals & clinics, Medical research centers, Academic institutes, Others), ...
$ 3450
Leprosy Treatment Comprehensive Study by Type (Borderline Tuberculoid, Tuberculoid, Borderline, Histoid, Others), Drug Type (Antibacterial, Leprostatics, Antitubercular, Others), Leprosy Type (Multib...
$ 3450
Malabsorption Syndrome Comprehensive Study by Application (Pharmaceutical Companies, Hospitals, Nutrition Clinics, Academic And Research Institutes), Treatment (Nutritional Supplements, Gluten-Free D...
$ 3750
Argininemia Treatment Comprehensive Study by Type (Oral, Injection), End Users (Hospitals, Clinics, Therapeutic Centres), Category (Congenital and Genetic Diseases, Metabolic disorders, RDCRN), Treat...
$ 3450
Dynamic SPECT Comprehensive Study by Application (Myocardial perfusion imaging, Functional brain imaging, Applications in nuclear technology, Others), Imaging Technique (Hybrid SPECT, Standalone SPEC...
$ 3750
Picato Gel Comprehensive Study by Type (Type I, Type II), Application (Actinic Keratosis, Keratosis), Distribution Channel (Direct Sale, Distributor) Players and Region - Global Market Outlook to 203...
$ 3500